JonesTrading Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price

Posted by Francis Steltz on Nov 9th, 2026

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) had its price objective boosted by stock analysts at JonesTrading from $20.00 to $31.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. JonesTrading‘s target price would indicate a potential upside of 66.67% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, October 2nd. HC Wainwright lifted their target price on Relay Therapeutics from $28.00 to $29.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. The Goldman Sachs Group upped their price target on Relay Therapeutics from $22.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Guggenheim reiterated a “buy” rating on shares of Relay Therapeutics in a report on Friday, August 7th. Finally, JPMorgan Chase & Co. boosted their price objective on Relay Therapeutics from $28.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Relay Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $27.00.

Read Our Latest Stock Report on Relay Therapeutics

Relay Therapeutics Stock Performance

RLAY opened at $18.60 on Friday. The firm has a market cap of $4.08 billion, a price-to-earnings ratio of -12.32 and a beta of 1.74. The firm’s 50-day simple moving average is $18.31 and its 200-day simple moving average is $15.20. Relay Therapeutics has a twelve month low of $5.95 and a twelve month high of $21.27.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.03. As a group, sell-side analysts anticipate that Relay Therapeutics will post -1.59 EPS for the current fiscal year.

Insider Transactions at Relay Therapeutics

In other news, major shareholder Pauling (Cayman) Ltd Svf sold 6,000,000 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $19.40, for a total transaction of $116,400,000.00. Following the completion of the transaction, the insider directly owned 21,904,963 shares in the company, valued at approximately $424,956,282.20. The trade was a 21.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Donald Bergstrom sold 8,530 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $18.97, for a total transaction of $161,814.10. Following the transaction, the insider owned 399,130 shares of the company’s stock, valued at approximately $7,571,496.10. This represents a 2.09% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 6,149,344 shares of company stock valued at $119,185,625. Corporate insiders own 5.04% of the company’s stock.

Institutional Investors Weigh In On Relay Therapeutics

A number of hedge funds have recently modified their holdings of the business. Legal & General Group Plc acquired a new position in shares of Relay Therapeutics in the 2nd quarter valued at approximately $2,389,000. California State Teachers Retirement System boosted its holdings in Relay Therapeutics by 47.9% during the first quarter. California State Teachers Retirement System now owns 174,099 shares of the company’s stock worth $1,732,000 after purchasing an additional 56,422 shares during the last quarter. Alphabet Inc. bought a new stake in Relay Therapeutics during the second quarter worth about $26,382,000. Persistent Asset Partners Ltd bought a new stake in shares of Relay Therapeutics during the 2nd quarter worth approximately $1,323,000. Finally, Sanctuary Advisors LLC acquired a new stake in Relay Therapeutics in the second quarter valued at $1,995,000. Institutional investors and hedge funds own 96.98% of the company’s stock.

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them.

Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.